Aspects of the subject disclosure may include, for example, detecting, by a substance delivery system coupled to a body part of an individual, an input signal not associated with a biological measurement of the individual, determining from the input signal, by the substance delivery system, whether delivering a dosage of a substance stored in the substance delivery system is needed and conforms to a dosage policy, and responsive to determining from the input signal that delivery of the dosage of the substance is needed and conforms to the dosage policy, initiating, by the substance delivery system, delivery of the dosage of the substance to the body part of the individual. Other embodiments are disclosed.
Legal claims defining the scope of protection, as filed with the USPTO.
2. The method of claim 1, wherein the minimum amount of time is based at least in part on an amount of the substance that will lessen an effectiveness of the substance when delivered to the individual.
4. The method of claim 3, further comprising adapting one or more of a procedure, a treatment, or a timer associated with the biological condition based at least in part on determining that the second dosage has improved the biological condition.
6. The method of claim 5, further comprising adapting one or more of a procedure, a treatment, or a timer associated with the biological condition based at least in part on determining that the second dosage has failed to improve the biological condition.
8. The system of claim 7, wherein the microfluidic delivery device comprises one or more micro-needles, one or more reservoirs configured to store the substance, and a piezo pump coupled to the one or more reservoirs and configured to deliver, in response to an instruction received from the one or more processors, the substance via the one or more micro-needles from the one or more reservoirs.
10. The system of claim 7, wherein the minimum amount of time is based at least in part on an amount of the substance that will cause an overdose of the substance when delivered to the individual.
12. The one or more non-transitory computer-readable media of claim 11, wherein the minimum amount of time is based at least in part on an amount of the substance that will lessen an effectiveness of the substance when delivered to the individual.
13. The one or more non-transitory computer-readable media of claim 11, wherein the microfluidic system comprises one or more micro-needles, one or more reservoirs configured to store the substance, and a piezo pump coupled to the one or more reservoirs and configured to deliver, in response to an instruction received from the one or more processors, the substance via the one or more micro-needles from the one or more reservoirs.
15. The one or more non-transitory computer-readable media of claim 11, further comprising preventing the second dosage from being delivered by the microfluidic system based at least in part on determining that the first time period is associated with a decrease in effectiveness of the substance.
Cooperative Patent Classification codes for this invention. Click any code to explore related patents in that topic.
February 18, 2021
July 2, 2024
Browse 5M+ US patents with plain-English claim translations and AI-generated analysis.